



“in three”

**An integrated
interdisciplinary approach to
animal-free nanomaterial
and chemical safety
assessment.**

Integrated in vitro and in silico tools

Paul Jennings

Vrije Universiteit Amsterdam

p.jennings@vu.nl

<https://www.estiv.org/in3/>



Funded by the **Marie Skłodowska-Curie Action** - Innovative Training Network under grant no. 721975.




To drive the synergistic development and utilisation of *in vitro* and *in silico* tools for human chemical and nanomaterial (NM) safety assessment.

<https://www.estiv.org/in3/>



Marie Gabrielle Zurich



Differentiation of **human induced Pluripotent Stem Cells (hiPSC)** to toxicologically relevant target tissues. The tissues, from the same genetic backgrounds, will be exposed to selected compounds and the data generated will be used to develop safety assessment approaches by integrating **cheminformatics**, **mechanistic toxicology** and **biokinetics** into computational models.


<https://www.estiv.org/in3/>



Sendai
Oct3/4, Sox2, Klf4, c-Myc

iPSC



differentiation



Core scientific activities

- Differentiation of well-characterised human iPSC into brain, lung, liver, kidney and vascular cells
- Delineation of tissue specific and donor specific effects of compound exposures (uptake, metabolism, excretion, and mechanistic toxicity)
- Development and optimisation of quantitative adverse outcome pathways (qAOPs) for each target organ which will be unified in an organism-level model
- Optimisation of QSAR and read-across tools for safety assessment
- Ultimately to create a unified expandable integrated testing strategy for chemical and NM safety assessment

<https://www.estiv.org/in3/>



<https://www.estiv.org/in3/>



Training Content and Structure

Block 1: Learning by Research

- ESRs research project
- Secondments to SMEs and other academic partners

Block 2: in3 virtual laboratory

- Collaboration with other ESRs in tasks
- Virtual Journal Club
- On-line reporting and presentations
- Data sharing
- Scientific paper writing

Block 3: Online learning

- 3Rs – from origins to implementation
- Regulation
- Hazard identification and risk assessment
- Chemical case studies
- Developmental biology and organogenesis
- Scientific writing, poster and oral presentations and grant writing

Block 4: On-site lecture and workshop series

- Adverse Outcome Pathway
- Good cell culture practice and iPSC
- In silico approaches
- Entrepreneurship and intellectual property
- Knowledge management and data integration
- Career development
- University doctoral programs

Block 5: Hands on technical workshops

- iPSC generation, culture and quality control.
- Toxicity assays.
- Methods for gene editing and reporter introduction.
- Nanomaterial manufacturing and characterisation.
- High content imaging.
- Modelling epithelial/ endothelial transport.
- Software training course.
- Building AOPs and OECD guidelines

Block 6: Communication and Dissemination

- Interaction and communication with in3 network
- Dissemination to scientific community
- Communication with public



Maxime Culot



“The scientists trained within in3 will acquire a unique multidisciplinary skill set and will be uniquely placed to support these activities in academia and industry within their future careers, giving them a competitive advantage and creating a project legacy”



<https://www.estiv.org/in3/>

Who are we in in3 ?

Beneficiaries

Vrije Universiteit Amsterdam, Molecular and Computational Toxicology, Prof. Dr. Paul Jennings. Coordinator.

Evercyte GmbH, Austria. Assoc. Prof. Regina Grillari / Assoc. Prof. Giovanni Grillari

Université d'Artois, France. BBB Laboratory. Assoc. Prof. Maxime Culot

University of Lausanne, Switzerland. Physiology. Marie-Gabrielle Zurich

BIOTALENTUM, Hungary. Prof. Andras Dinnyes

University of Leuven, Leuven, Belgium. KU Leuven Stem Cell Institute, Prof. Catherine Verfaillie

Department of Health – Public Health England, United Kingdom. Toxicology Dept./Centre for Radiation, Chemical and Environmental Hazards/Nanotoxicology Laboratory. Dr. Martin Leonard.

Newcells Biotech, United Kingdom. Prof. Lyle Armstrong

Istituto di Ricerche Farmacologiche Mario Negri, Italy. Environmental Health Sciences/Laboratory of Environmental Chemistry and Toxicology. Prof. Emilio Benfenati

Liverpool John Moores University, United Kingdom. School of Pharmacy and Biomolecular Sciences. Prof. Mark Cronin

National Institute of Chemistry, Ljubljana, Slovenia. Laboratory of Chemometrics. Prof. Marjana Novič

Universiteit Utrecht, The Netherlands. Institute for Risk Assessment Sciences/Toxicology. Ass. Prof. Nynke Kramer

Douglas Connect, Switzerland. Dr. Barry Hardy / Dr. Thomas Exner

Partner Organisations

Center for Alternatives to Animal Testing – EUROPE, Universität Konstanz, Germany. Dr. Mardas Daneshian

European Union Reference Laboratory for alternatives to animal testing, Italy. Institute for Health and Consumer Protection, European Commission Joint Research Centre. Dr. Anna Price

European Society of Toxicology in vitro, The Netherlands. Prof. Mathieu Vinken

Nanocomposix Europe, Czech Republic. Karolina Sauerova

L'Oreal, France. Gladys Ouedraogo

Academic and governmental



Companies




Organisations





Nicoleta Spinu



Leonie Fransen



Sara Wellens



Ivo Djidrovski



Sreya Ghosh



Cormac Murphy



Vidya Chandrasekaran



Susana Proença



Zahra Mazidi



Aurore Bourguignon



Liadys Mora Lagares



Kristijan Vukovic




Pranika Singh



Carolina Nunes



Ana Yisel Caballero



dedicated, motivated, dynamic,
passionate, hard working,
intelligent, fun, social,
responsible, diverse

In Vitro

In Silico




Development and Use of Adverse Outcome Pathway (AOP) Networks Within The in3 Project




ESR Nicoleta Spinu
PI Mark Cronin

Nicoleta Spinu




AIM: To describe the development and use of AOP networks, focusing on those relevant for in3 project selected organs and suitable for further quantitative modelling.





Towards bioinformatics workflow for prediction of chronic kidney disease based on iPS cell data

Pranika Singh, Thomas Exner



Introducing *ab initio* QSAR, a versatile tool for regression and classification

Kristijan Vukovic, Emilio Benfenati




Development of *in silico* classification models to predict the toxicity of azoles as aromatase or not aromatase inhibitors

Ana Caballero Alfonso, Emilio Benfenati





Structural Alerts



P-glycoprotein modelling: a combined in silico approach towards identification of safer chemicals

Liadys Mora Lagares, Marjana Novič, Nikola Minovski



MSCA-ITN-2016
grant no. 721975



KEMIJSKI INŠTITUT

Evaluation of models to estimate the distribution kinetics of test chemicals *in vitro*


Susana Proença, Nynke Kramer



Universiteit Utrecht



MSCA-ITN-2016
 grant no. 721975



IPSCs DIFFERENTIATION TO ENDOTHELIAL CELLS AS MODL SYSTEM FOR *IN VITRO* TOXICOLOGY


Zahra Mazidi, Johannes Grillari, Regina Grillari, Mathias Wieser



iPS cell aggregates


Endothelial colony forming cells

Mature endothelial cells




Protocol comparison for deriving BBB-models from iPSCs for use in toxicological assessment of chemicals

Sara Wellens, Maxime Culot




Human brain: 650 km of capillaries
Surface area : 20m²


Lippmann *et al.* Scientific Reports, 2014



Hollmann *et al.* Fluids Barriers CNS, 2017






Qian *et al.* Science Advances, 2017






iPSC-DERIVED HUMAN 3D BRAIN MODEL FOR NEUROTOXICITY TESTING



Carolina Nunes, David Pamies, Marie-Gabrielle Zurich






Evaluation of iPSC derived renal proximal tubular epithelial cells for toxicity assessment




Vidya Chandrasekaran, Prof. Dr. Paul Jennings








The development and optimisation of iPSC-derived podocytes and their integration into a glomerular model for toxicity testing

Cormac Murphy, Anja Wilmes, Paul Jennings




Differentiation of hepatocyte-like cells from induced pluripotent stem cells (iPSCs) and application to hepatotoxicity testing

Sreya Ghosh, Prof. Dr. Catherine M. Verfaillie




DEVELOPMENT OF iPSC-DERIVED SMALL AIRWAY MODELS AND APPLICATION TO TOXICITY TESTING

Leonie Fransen, Dr. Martin Leonard



McCaughey, K. B., Hawkins, F., Serra, M., Thomas, D. C., Jacob, A., & Kotton, D. N. (2017).

VitroCell® exposure system



Development of iPSC derived Conducting Airways and application to toxicity testing

Ivo Djidrovski, Mike Nicholds, Lyle Armstrong



Development of a cellular toxicology model using genetically engineered human induced pluripotent stem cells.


Aurore Bourguignon, Julianna Kobolák, András Dinnyés



Integrated Approaches to Testing and Assessment



Read Across and QSAR



* Reporters

iPSC




differentiation

Gene editing

- P - glycoprotein
- MATE-1
- BSEP

Toxicity testing





An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment.



Milan, April 2018



Dr. Ellen Langemeijer
e.v.langemeijer@vu.nl
estiv.org/in3

Funded by the Marie Skłodowska-Curie Action - Innovative Training Network under grant no. 721975.